(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of -3.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 152.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Maravai Lifesciences Holdings's revenue in 2025 is $259,185,000.On average, 5 Wall Street analysts forecast MRVI's revenue for 2025 to be $49,713,000,363, with the lowest MRVI revenue forecast at $47,177,017,274, and the highest MRVI revenue forecast at $53,944,640,784. On average, 5 Wall Street analysts forecast MRVI's revenue for 2026 to be $55,791,882,303, with the lowest MRVI revenue forecast at $53,664,871,313, and the highest MRVI revenue forecast at $58,606,108,848.
In 2027, MRVI is forecast to generate $82,187,368,912 in revenue, with the lowest revenue forecast at $64,288,481,146 and the highest revenue forecast at $100,086,511,014.